The Technical AnalystExchange: STO Sector: Healthcare Industry: Medical Instruments & Supplies
AegirBio AB (publ) Price, Forecast, Insider, Ratings, Fundamentals & Signals
-4.53% SEK0.590
America/New_York / 17 mai 2024 @ 11:21
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 18.22 mill |
| EPS: | -18.59 |
| P/E: | -0.0300 |
| Earnings Date: | Apr 26, 2024 |
| SharesOutstanding: | 30.88 mill |
| Avg Daily Volume: | 0.195 mill |
| RATING 2024-05-17 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | |||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0300 | sector: PE 19.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0300 | industry: PE 20.76 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
SEK 0.510 - 0.670 ( +/- 13.56%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | SEK0.590 (-4.53% ) |
| Volume | 0.216 mill |
| Avg. Vol. | 0.195 mill |
| % of Avg. Vol | 110.38 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AEGIR.ST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
AEGIR.ST
AegirBio AB (publ), a diagnostic company, develops and commercializes tests to follow the dosage of biological drugs. The company focuses on therapeutic drug monitoring of biologic therapies in the multiple sclerosis, cancer, and autoimmune diseases. It offers moNATor, a first dose-monitoring laboratory test to test multiple sclerosis for healthcare professionals and patients; and Viraspec, a COVID-19 saliva test kit. The company was incorporated in 2019 and is based in Lund, Sweden.